Ingevity Co. (NYSE:NGVT) Shares Bought by Marshall Wace LLP

Marshall Wace LLP grew its position in Ingevity Co. (NYSE:NGVT - Free Report) by 5.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 207,005 shares of the company's stock after purchasing an additional 11,407 shares during the period. Marshall Wace LLP owned approximately 0.57% of Ingevity worth $8,435,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. KBC Group NV raised its holdings in shares of Ingevity by 27.5% during the fourth quarter. KBC Group NV now owns 2,007 shares of the company's stock worth $82,000 after purchasing an additional 433 shares during the last quarter. Empowered Funds LLC purchased a new position in shares of Ingevity during the 4th quarter valued at about $187,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Ingevity in the 4th quarter valued at about $214,000. Teacher Retirement System of Texas purchased a new stake in shares of Ingevity in the fourth quarter worth about $237,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in Ingevity during the fourth quarter worth about $239,000. 91.59% of the stock is currently owned by hedge funds and other institutional investors.

Ingevity Price Performance

Ingevity stock opened at $31.70 on Wednesday. The company has a debt-to-equity ratio of 6.86, a quick ratio of 1.04 and a current ratio of 1.87. The stock has a market capitalization of $1.16 billion, a P/E ratio of -2.68 and a beta of 1.54. Ingevity Co. has a 1 year low of $28.49 and a 1 year high of $56.30. The company's fifty day moving average price is $40.40 and its 200 day moving average price is $41.80.

Ingevity (NYSE:NGVT - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.66. Ingevity had a negative net margin of 30.60% and a positive return on equity of 41.44%. The firm had revenue of $298.80 million during the quarter, compared to the consensus estimate of $297.40 million. As a group, equities research analysts anticipate that Ingevity Co. will post 4.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on NGVT shares. BMO Capital Markets raised Ingevity from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $62.00 to $65.00 in a report on Wednesday, February 26th. StockNews.com cut shares of Ingevity from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Finally, Wells Fargo & Company dropped their price target on shares of Ingevity from $45.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $52.20.

Ingevity Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.